Liver International
@LiverInt
Followers
7K
Following
547
Media
524
Statuses
2K
We publish high-quality original research in Hepatology / Co-EICs @lucavalenti75 @AghemoAlessio @Alexfornergon / IF=6.0 / RT ≠ endorsment
#LiverTwitter
Joined November 2012
🔥 🆙 to publish this work with @HD3vedi and team regarding the importance of #exercise across all types and stages of steatotic liver disease! Check it out here: https://t.co/EJ3rUBdeJC
onlinelibrary.wiley.com
Background The increasing prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), parallels the rise in sedentar...
4
39
124
You can continue #Anticoagulation when you perform #endoscopicbandligation #ELB for #varices When Undergoing Endoscopic Variceal Ligation: A Systematic Review and Meta‐Analysis @LiverInt 🔗 https://t.co/JzIVTJJ4Mm
2
28
63
Anticoagulation did 🚫increase the risk of bleeding With/without anticoagulation during EVL, we found a similar risk of: 1) Overall bleeding 2) Severe bleeding 3) Post-banding ulcer bleeding #Livertwitter 👉 https://t.co/gWNPZK58in…
@FromGumtoBum @ASGEendoscopy @ESGE_news @drkeithsiau @CarlKayMD @RashidLui @AnandVKulkarni2 @JustSagnik @Sanchit30497977 @BavenoCoop @AASLDtweets @EASLnews Indeed, the practice of anticoagulation is heterogeneous. We recently summarized the existing studies looking at the safety of anticoagulation in patients undergoing EVL 👉 https://t.co/gWNPZK58in Anticoagulation did 🚫increase the risk of bleeding
1
16
40
Very excited to have the final paper from my #PhD published #OpenAccess in @LiverInt While #HCV DAA treatment is highly effective, it is important to understand why a small minority are not cured. We aimed to do this with data from 🇦🇺🇨🇦🇫🇷🇳🇱🇪🇸🇨🇭 https://t.co/qBUoZ1gVni
0
4
7
In this @LiverInt study, researchers from #Japan shed light on how #MICOS defects impair #mitochondrial function in #MitochondrialDNAdepletionSyndrome, opening new avenues for genetic testing and therapies. Learn more:
3
11
119
2/2 💡 The clinical impact? Using genetics to interpret LBTs may reduce false positives/negatives, optimize resources, and improve diagnostics further validation in diverse populations is needed! 🌍🩺 #livertwitter
0
0
2
1/2 ⬆️ liver tests may not always indicate a higher risk of serious liver disease Genetic variants influencing common liver test results (like GGT & bilirubin) don't always correlate with higher cirrhosis risk 🤔 🔓 https://t.co/BbKxvgLqxF
#livertwitter
1
11
16
The number and type of metabolic syndrome traits have important impacts on the risk of CKD and incident ESRD in people with MASLD. @EScorletti, @Alessan95336031, @LiverInt Read our recent work here: https://t.co/eV0gBxEJQF
onlinelibrary.wiley.com
Background and Aims The impact of metabolic syndrome (MetS) traits on chronic kidney disease (CKD) risk in metabolic dysfunction-associated steatotic liver disease (MASLD) is unknown. We investigat...
0
4
8
🚨 Out now in @LiverInt: New scenarios in LT for HCC 👥 Led by a great international team in the field. @Alexfornergon @goncrespo1 @A_DAlessioMD @DJPinato @ColmeneroJordi @liverunitclinic @hospitalclinic @idibaps @BCLC_group @CHBPaulBrousse @HUReinaSofia
https://t.co/tIPAsYHT7n
onlinelibrary.wiley.com
Background and Aims Despite liver transplantation (LT) is considered the optimal treatment for hepatocellular carcinoma (HCC), particularly in patients with impaired liver function, the shortage of...
2
11
32
G-CSF is not inferior to corticosteroids in improving 90-day overall survival and 6-months transplant free survival in patients with severe alcohol-associated hepatitis. Singh et Al @LiverInt
https://t.co/jYQn4fd9nf
#livertwitter #GITwitter
0
3
6
Our latest review on the impact of #PNPLA3 variants on clinical outcomes in #MASLD is out in @LiverInt open access @salvatore_petta @lucavalenti75 @stefano_romeo76
https://t.co/cZM8XXEeps
onlinelibrary.wiley.com
Background and Aims Metabolic dysfunction-associated steatotic liver disease (MASLD) is a heterogenous clinical and histopathological entity, where multiple metabolic co-factors are intertwined...
0
8
17
🚨 New Research Alert! 🚨 Latest paper in @LiverInt by the @OhioStateSurg TEAM explores the impact of #GLP1RA on adverse liver outcomes among patients with #Alcohol associated #liver disease and type 2 #diabetes Link 👉 https://t.co/f4FB7N0W3w 💡Key finding GLP-1RA = ⬇️
0
4
10
🔴Our work about the burden of hepatitis D in the context of reflex testing has received over 500 views since publication! 📃Read it here https://t.co/wrn7Pa9XuC
#ViewsMilestone
@Mariabutif @AEEHLiver @LiverInt
onlinelibrary.wiley.com
Chronic hepatitis D (CHD) is a severe form of viral hepatitis that leads to liver cirrhosis and hepatocellular carcinoma. CHD is underdiagnosed, and this study aimed to assess the impact of hepatit...
0
1
1
What a news from @LiverInt! 🥳 Our review on CARVEDILOL IN PORTAL HYPERTENSION has received over 20,000 views since publication! 🥰 @ReibergerThomas @VincenzoLaMura @GiovanniVitale 🔽 https://t.co/MWOL0wJGkb
#ViewsMilestone
onlinelibrary.wiley.com
Portal hypertension (PH) is the most common complication ofcirrhosis and represents the main driver of hepatic decompensation. The overarching goal of PH treatments in patients with compensated...
0
6
47
Necesidades no cubiertas en pacientes con hepatitis autoinmune (y son unas cuantas): 👉 Solo el 62% de los pacientes logran respuesta completa tras 1 año de tto ⚠️ Apenas el 27% lo consigue sin esteroides 🔄 30% de los pacientes cambian de tratamiento por intolerancia o no
1
18
38
🚨#livertwitter
#Hepatitis #HCV #Elimination 🇦🇹 Austrian #HCV Elimination Project supported @GileadSciences 5695 #HCV patients screened 397 started on #Antivirals #DAA 326 #HCV patients cured #SVR ✅ #HepC Cure 😇 Survival Benefit 📕@LiverInt 🔗 https://t.co/mBPSTF58aR
1
3
16
New insights into liver fibrosis in @LiverInt! SHG/TPEF microscopy with #AI offers precise assessment of #fibrosis in MASH F3 patients, revealing changes even when standard scoring shows 'no change.' #livertwitter @DavidKleiner12
https://t.co/GO2PLIHI24
0
6
21
“The Liver would be better” The story behind Neruda’s ode to the liver by @MarcoArreseMD in @LiverInt
https://t.co/vTA8MuXkWM
4
16
49
Just recently published at @LiverInt , our work on waitlist outcomes and post-transplant outcomes in MASLD/AIH. We found better waitlist outcomes on MASLD/AIH compared to MASLD and AIH. No differences on post-LT outcomes.@BonderAlan @HD3vedi @AnaMarencoMD
https://t.co/XRTMk2fhJX
onlinelibrary.wiley.com
Background and Aims Metabolic dysfunction-associated steatotic liver disease (MASLD), in the context of autoimmune hepatitis (AIH) among liver transplantation (LT) candidates or recipients remains...
1
6
23
2/2 ‼️ Despite its efficacy, 31% of patients experienced relapses, successfully managed with additional Rituximab cycles While promising, prospective studies are needed to validate these findings in advanced #AIH
#livertwitter
0
4
11